Importantly, the combination of 5μM cytarabine and 5 μg/mL anti-CD44 increased apoptosis of primary AML cells more than the additive effect of either alone, supporting the hypothesis that forcing AML cells out of the protective BM niche will render them more susceptible to standard therapies. The gene discussed is CD44; the disease is acute myeloid leukemia.